Relapse after apparently successful treatment of coccidioidomycosis has been a problem with both amphotericin B and the azoles. We conducted a retrospective cohort study of 34 patients who required therapy for coccidioidomycosis between 1973 and 1993; 10 relapsed and 25 (one patient received two courses of therapy) did not relapse during follow-up. The mean time to relapse after completion of therapy was 7.3 months (range, 1 -21 months). All 34 patients responded clinically to therapy. A fourfold or greater decrease in titers of antibody, as determined by complement fixation (CF), during therapy was seen in seven (78%) of nine patients who relapsed and 17 (85%) of 20 patients who did not relapse ( P Å .956). There was no significant difference between relapsers and nonrelapsers in terms of the lowest CF titer during therapy, the CF titer at the end of therapy, or the peak CF titer. The risk of relapse was increased among those with a peak CF titer of §1:256 (relative risk [RR] Å 4.7; 95% confidence interval [CI] Å 1.4 -16.1), as compared with patients who did not mount such a high antibody response. Similarly, the risk of relapse was higher among those with serially negative coccidioidin skin tests (CSTs) than those with serially positive CSTs (RR Å 4.8; 95% CI Å 1.2 -19.5). We conclude that clinical response, lowest CF titer, end-of-therapy CF titer, and decrease in the CF titer of at least fourfold are not predictive of relapse in patients with coccidioidomycosis. Negative serial coccidioidin skin tests and a peak CF antibody titer of §1:256 are independently associated with increased risk of relapse.
Coccidioidomycosis has long been recognized as one of the Some authors have suggested that the azoles act as ''pharmacological suppressants,'' and that some patients may anticipate most difficult endemic mycoses to treat. The rates of relapse after apparently successful treatment with amphotericin B have ''prolonged if not indefinite suppressive therapy'' [11] .
We retrospectively reviewed our 20-year experience in the not been well defined, but relapse has been recognized as a problem since the drug was first used in the treatment of coctreatment of nonmeningeal coccidioidomycosis in an attempt to define those clinical or laboratory parameters that might cidioidal infections in the late 1950s. [1] Relapse rates in prospective studies of the azoles have ranged from 16% to 67%, predict which patients would be most likely to relapse after treatment. with a reasonable estimate of 25% -35% after therapy [2 -10] .
See editorial response by Stevens, pages 1211 -2.
Methods
We conducted a retrospective review of the records of paSince the introduction of the less toxic oral azoles, the decitients with coccidioidomycosis who were evaluated at the sion to begin treatment of a patient with coccidioidomycosis Naval Medical Center, San Diego, between 1973 and 1993. has become easier. Conversely, because the azoles are inhibi-
The Naval Medical Center serves as the infectious disease and tory but not fungicidal, the specter of relapse has made the pulmonary referral center for all active duty and retired military decision of when to stop therapy increasingly more difficult.
personnel in Southern California. To be included, a patient had to have completed therapy, had to have undergone serial serological (complement fixation [CF]) or coccidioidin skin For those who relapsed, the mean duration of follow-up was 9.4 years, with a mean time to relapse these patients met the study criteria. Of the 60 patients not included in the study, no therapy was indicated for 17, 16 of 7.3 months. For nonrelapsers, the mean duration of follow-up was 3.5 years. The mean duration of follow-up was continued to receive therapy, three had meningitis at the time of the study, three relapsed while still receiving therapy, and longer for patients with disseminated disease who did not relapse (4.9 years) than for those with disease confined to two died while receiving therapy. Nineteen patients were not included because of inadequate follow-up or because they had the chest (1.9 years). Only two of the 25 nonrelapsers received õ6 months of follow-up. not undergone serial serological tests or skin tests, predominantly because they had been referred from distant military Treatment. The patients who subsequently relapsed received a mean dose of 4.1 g of amphotericin B (range, 2.0 -installations, had been transferred, or had left the military.
Of the 34 patients studied, 10 relapsed, and 25 did not relapse 9.9 g). Two of the 10 patients had both received an additional 17-month course of ketoconazole before their relapses. For the (one patient received two separate courses of therapy). Ten of the patients were female, and 25 were male; ages ranged from patients who did not relapse, the mean dose of amphotericin B was 2.1 g (range, 0.6 -4.8 g). Five patients received addi-16 years to 64 years. There was a trend toward more relapses among the males: nine (36%) of 25 men relapsed, compared tional azole therapy for a mean duration of 15.4 months. Ten of the patients who did not relapse received azole therapy alone with only one (10%) of 10 of the women ( P Å .26).
Eleven of the patients (32%) were Caucasian, 14 (41%) were (eight received ketoconazole and two received fluconazole) for a mean duration of 10.7 months. One patient who did not Filipino, eight (24%) were black, one was Guamanian, and one was Asian. The racial composition of our total population relapse during 21 months of follow-up had cutaneous dissemination of the disease but was not treated. eligible for care within 100 miles of the referral center was 67% Caucasian, 15.2% African-American, and 8.6% Asian or
Relapses. The mean time to documentation of relapse after apparent successful completion of therapy was 7.3 months Pacific Islander. As seen in table 1, two (18%) of 11 Caucasians, five (35.7%) of the 14 Filipinos, and three (37.5%) of (range, 1 -21 months). Six of the relapses involved the skin, three involved joints, and one was a paravertebral abscess (table the eight blacks relapsed. In this small sample, the difference in relapse between races was not statistically significant.
3). Relapses resulted in extensive additional treatment. Three patients received repeated courses of amphotericin B, and five There was a broad spectrum of coccidioidal involvement: 22 patients had disseminated extrapulmonary disease (cutareceived additional azole therapy. Azole therapy was prolonged in four patients. One patient each was treated for an additional neous or soft-tissue involvement, 12 patients; bone or joint involvement, 6; liver involvement, 2; ocular involvement, 1; 8.5 years and 11 years, while two patients continue to receive therapy (total durations, 15 and 18 years). and laryngeal involvement, 1) (table 2). Eight patients had 
Serial monitoring of CF titers during therapy revealed that 85% of those who did not relapse and 78% of those who relapsed had also evaluated. There was a fourfold or greater increase in CF titers after completion of therapy for four of eight relapsers, as compared with three (14%) of 21 nonrelapsers (RR Å 3.14; 95% Prediction of relapse. All patients responded clinically to CI Å 1.05-9.39). Serial CF test results were not available for six therapy and were asymptomatic when therapy was completed.
patients during follow-up. Of the patients with progressive pulmonary disease who were A total of 172 CSTs were performed at a 1:100 dilution for at high risk for future dissemination (they had persistent sympthese 34 patients. Results of serial skin tests performed during toms and rising CF titers, and they were African-American or and after completion of therapy were available for 33 patients. Filipino), none of 8 relapsed after therapy, whereas 10 of 22
Seven of 14 patients with serially negative CSTs relapsed, with extrapulmonary dissemination before therapy relapsed whereas two of 19 with serially positive CSTs relapsed ( P Å .029).
(RR Å 4.8; 95% CI Å 1.
-19.5). When the CF test results at the completion of therapy were
Multivariate logistic regression modeling revealed that a negaused as predictors of relapse, there was no difference in risk tive SCST and a peak CF titer of §1:256 were independently of relapse for patients with a CF titer of õ1:4 than for those associated with relapse (ORs Å 5.7 [90% CI Å 1.1-28] and 5.4 with a higher CF titer (RR Å 1.0; 95% CI Å 0.3 -2.9). Five [90% CI Å 1.1-27.1], respectively). of the 10 patients with a CF titer of §1:16 at the end of therapy
The positive predictive value of negative SCSTs and of peak relapsed, and five did not. In fact, only one of the two patients CF titers of §1:256 for future relapse were 50% and 62.5%, with the highest CF titers at the completion of therapy (1:128) respectively. The predictive value for successful therapy withrelapsed, and the other did not.
out relapse was 89.4% for positive SCSTs (17 of 19 patients On evaluating the lowest CF titers during therapy, nine with positive SCSTs did not relapse). If the peak CF titer was (90%) of 10 who subsequently relapsed had a CF titer of £1:8.
õ1:256, there was an 81% predictive value of no future relapse For 18 (78%) of 23 nonrelapsers, the lowest CF titer was £1:8.
(22 of 27 patients remained relapse free). For serial CF tests, For two patients, CF titers were not obtained during therapy.
if there was no fourfold or greater increase in CF titers during The peak CF titer measured was §1:256 for five of 10 relapsers but only three (12%) of 25 nonrelapsers (RR Å 4.7;
follow-up, the predictive value for not relapsing was 82.6%. 
Discussion
In the search for an objective measure of therapeutic success to guide clinicians, serological response has been one of the In a classic monograph published in 1958, Fiese [12] noted criteria most consistently advocated. Winn [1] promoted serothat the treatment of coccidioidomycosis was a subject ''to be logical response as the ''ultimate criterion for true effectiveness approached with humility.'' The treatment of this endemic funof amphotericin B'' in his earliest studies. He concluded that gal infection has been difficult because of the lack of a rapidly serological evaluation was ''the most important single critefungicidal agent, the myriad clinical presentations, and the unrion'' for estimating response to therapy [17] . The serological predictable clinical course. Mackler [13] noted that coccidioicriterion most commonly suggested has been a decrease in CF domycosis was ''a disease without a natural history,'' and titers to £1:16. However, this decrease proved an elusive goal Winn [14] noted that it ''possessed a bizarreness that defies in the days of toxic amphotericin B therapy, when only one of classification.'' These same factors make the evaluation of resix patients treated by Sanford et al.
[16] had a decrease in sponse to therapy and the prediction of subsequent relapse titer to £1:16, and only seven of 22 achieved this serological exceptionally difficult.
response in Winn's initial series [1] . In the current series, proRelapses after apparently successful treatment of coccidioilonged treatment with azoles allowed a decrease in the CF titer domycosis have been recognized since the introduction of the to £1:16 during therapy for 28 of 31 patients. However, this first known effective therapy, amphotericin B. Winn [14] noted decrease did not help predict a durable response to therapy as three relapses among the first 22 patients he described in 1959, seven of 28 patients who achieved this serological response including one patient with progressive pulmonary disease who relapsed, as compared with three of six patients who had CF relapsed with meningitis after completing a course of treatment titers of §1:16 at the end of therapy ( P Å NS). A second with 2.5 g of amphotericin B. Relapse has continued to be a recommendation has been to achieve at least a fourfold reducsignificant problem since the introduction of the oral azole tion in titer rather than a reduction below an absolute level. In antifungals. The rate of relapse after treatment with ketoconathe present study, almost all patients had fourfold or greater zole has ranged from 23% to 58% [3 -5] , and the relapse rates reductions in CF titers (i.e., 85% of those who did not relapse after treatment with itraconazole have ranged from 16% to vs. 78% of those who did relapse). 25% [8 -10] . In a recently reported trial of fluconazole, a 37%
For predicting relapse, there would be many advantages to overall relapse rate was noted despite an average therapeutic the serial measurement of CF titers during therapy. The CF course of 1.5 years [7] . Relapse rates varied from 50% for test is standardized, convenient, reproducible, and quantifiable. bone and joint disease to 39% for chronic pulmonary disease Unfortunately, at least from an analysis of our data, changes to 23% for skin and soft-tissue infections. The high relapse of CF titers in response to therapy do not seem to be predictors rate should not be surprising, as azoles are inhibitory, not fungiof relapse. However, if the CF titer is presumed to be a crude cidal. In fact, some authors have suggested that azoles act as indicator of the coccidioidal burden (i.e., an ineffective antipharmacological suppressants, and the need for prolonged, if body response that increases proportionate to the antigenic funnot indefinite, suppressive therapy should be expected [11] .
gal load), then the peak CF titer might correlate with the heaviRelapse had significant consequences in our study. Three est fungal burden and risk of relapse. Indeed, we found that a patients received repeated courses of amphotericin B, and five peak CF titer of §1:256 was a significant and independent received prolonged courses (8.5 years, 11 years, 16 years, and predictor of relapse. 18 years) of azoles. Two of the patients may well receive Unfortunately, CF titers are known to vary from laboratory lifelong azole therapy because of patient and physician relucto laboratory, and thus this particular titer ( §1:256) may not tance to risk further relapses.
be generalizable. However, as has been recognized since the Drutz [15] has suggested that ''the ultimate goal of therapy seminal work of Smith et al. [18] , an increased risk of dissemiis marked clinical improvement, healing of all apparent lesions, nation is associated with a CF titer ranging from 1:16 to 1:32. a reduction of antibody titers to stable low levels (at least a This threshold appears to have withstood the test of time. It 4-fold titer decline), and maintenance or restoration of skin test may also be reasonable to presume that a particular peak CF reactivity to coccidioidin.'' We focused on clinical response, titer might be associated with an increased risk of relapse. changes in the complement fixation titer, and dermal sensitivity Unfortunately, the CF test at best appears to be a crude surroto coccidioidin in attempting to define predictors of relapse gate of fungal load and does not reflect the status of the host after therapy for coccidioidomycosis.
cell -mediated immunity to C. immitis, which must be intact Clinical response has long been noted to be a minimum, but if antifungal therapy is discontinued and relapse is to be preoften inadequate, criterion for success. In 1962, Sanford et al.
vented.
[16] noted that ''an objective basis for terminating therapy There were significantly more relapses among patients who other than the elusive one of clinical improvement is needed had a fourfold or greater increase of CF titer after completion urgently.'' This was certainly true in our series, where all paof therapy. Because the increase in CF titer was measured after tients had a complete clinical response before termination of completion of therapy, this level would not help answer the therapy. Despite this clinical response, 10 (28.5%) of 35 courses ended with relapse.
critical question of when therapy can safely be discontinued.
/ 9c3f$$no73 10-17-97 22:25:11 cida UC: CID However, monitoring of the CF titer may be reasonable for size and the results of in vitro studies of CMI has been poor [27, 28] . The failure to develop dermal hypersensitivity may determining which patients are at increased risk of relapse and need more intensive follow-up.
reflect persistence of an ineffective type 2 helper cell response, with depression of CMI and an elevated antibody response The coccidioidin skin test has long been recognized as an important prognostic indicator. In the days before effective [29] . Perhaps, as noted by Smith et al. [18] , those patients with persistently negative skin tests are at risk of relapse because therapy was available, Fiese [12] noted that recovery from coccidioidal granuloma was often accompanied by reestablishof ''the continuing vulnerability of the immunologically defective.'' ment of sensitivity to coccidioidin. Smith et al. [18] noted that the survival rate was 75% without treatment among patients
There are numerous problems associated with the use of SCSTs, including those problems generic to skin testing and with disseminated disease and a positive coccidioidin skin test (dilution, 1:100), whereas it was 17% among those with negathose specific to coccidioidin. In general, skin testing requires two visits, and ideally three for each test (tests are read at 24 tive skin tests. Kelly et al. [19] noted a 67% survival rate for skin test -positive patients with coccidioidal meningitis, while and 48 hours), and the problem of interobserver variability is well known. In addition, batches of coccidioidin vary in pothis rate was 0 for skin test -negative patients. Drutz [15] noted that ''patients with disseminated coccidioidomycosis whose tency, tests for standardizing different lots are lacking, and potency of the original coccidioidin reference standard may skin tests are persistently negative are more likely to require prolonged treatment and are more likely to relapse.'' In fact, decrease [30] . Most investigators agree that induction of sensitivity by repeated testing is not a problem [17] . However, one Einstein [20] has suggested that ''perhaps all that is really needed of an antifungal chemotherapeutic agent is to keep the article suggested that simultaneous testing with two strengths of spherulin and two strengths of coccidioidin could induce patient alive until host factors can take over.'' At our institution, we have used SCSTs for ú25 years. sensitivity in 18.6% of patients whose tests were initially negative [31] . Hence, we were able to look at both initial skin test status and the dynamics of skin test reactivity across time. We did not
Although there are significant problems with SCSTs, they remain the only dynamic test we studied that could be monifind the initial skin test results helpful in predicting relapse, as three (20%) of 15 who relapsed and seven (37%) of 19 who tored during therapy and were capable of predicting a sustained, relapse-free response to therapy. These tests also remain the did not relapse had initially positive tests. However, we found that when patients had two or more consecutive positive skin only readily available measure of CMI, which most authors agree is central to host defense against C. immitis. A more tests before completion of therapy, only two (11%) of 19 subsequently relapsed. The one patient with disseminated cutaneous convenient and reproducible measure of CMI to C. immitis would be a significant advance in the prediction of relapse after disease who did not receive therapy and did not relapse during 21 months of follow-up had positive SCSTs. Conversely, seven therapy. With respect to positive predictive value, neither negative of 14 patients with negative SCSTs relapsed after completion of therapy. In addition, all three patients (not included in this SCSTs nor a CF titer of §1:256 was especially reliable (predictive values, 50% and 62.5%, respectively). However, posiseries) who relapsed while still receiving therapy also had negative SCSTs.
tive SCSTs and a peak CF titer of õ1:256 had a much better predictive value for determining which patients would not reAlthough serial positive skin tests are apparently strong predictors that patients will not relapse, serial positive skin tests lapse (predictive values, 89.4% and 81%, respectively). If there was no fourfold or greater increase in the CF titer during are by no means infallible. Skin test reactivity is a dynamic process, and we have seen patients' skin tests revert to negative, follow-up, the predictive value for not relapsing was 82.6%. There were a number of factors that showed a trend toward with subsequent relapse. Catanzaro [21] noted four patients who developed reactivity to coccidioidin but later had reactivastatistical significance, and these factors should be more closely studied during prospective treatment trials. This is especially tion of their disease.
Theoretically, the use of SCSTs is plausible because data true because the current series was retrospective and involved a small sample size. Race, sex, and site of disease should be from animal studies [22, 23] and clinical experience [24 -26] support the role of cell-mediated immunity (CMI) in protecting evaluated as potential predictors of relapse in future treatment trials. the host from progressive disease due to C. immitis. The skin test is a measure of the cell-mediated immune response to intradermal coccidioidin. However, there is controversy as to Conclusion the best measure of CMI (i.e., the skin test induration, lymphocyte transformation, or monocyte production of IL-2 and Our retrospective cohort study of 34 cases of nonmeningeal coccidioidomycosis revealed that a peak CF titer of §1:256 IFN-g). Some authors have found skin test induration to be the most sensitive measure, while others have found lymphocyte and negative SCSTs were independently associated with relapse after completion of therapy. No similar associations with transformation more sensitive, and some have found these measures to be equal [26 -28] . Correlation between the induration relapse were found for initial coccidioidin skin tests, a fourfold
